Low Risk of Drug Interaction between the Cyclophilin Inhibitor Debio-025 and (Peg) IFNa/ribavirin in HCV | Debio 025 | /

Home|Careers|Contact us

Welcome

At a glance

Social responsibility

Our companies

Business Model

Development capabilites

News

27.04.2010
Debiopharm Group™ starts Phase I clinical trial with Debio 0932
26.04.2010
Two New Tenants for EPFL’s Innovation Square

Low Risk of Drug Interaction between the Cyclophilin Inhibitor Debio-025 and (Peg) IFNa/ribavirin in HCV

L. Novaroli, V. Nicolas, M.P. Simonin, A. Menetrey, N. Treijtel, I. A.T.M. Meerts, H. Porchet, R. Crabbé

17th APASL Conference, Viral Hepatitis and Hepatocellular Carcinoma - March 2007 - Kyoto/Japan 2007 (Abstract)